Merck is stopping a phase 3 trial of its mega blockbuster anti-PD-1 therapy Keytruda (pembrolizumab) in combination with AstraZeneca’s blockbuster PARP inhibitor Lynparza (olaparib) for prostate cancer after an independent data monitoring committee recommended it do so.
Source: Drug Industry Daily